The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤ 18 Years Old.

Giles Senyurek, Yasemin; Iscan, Ahmet; Sormaz, Ismail; Poyrazoglu, Şükran; Tunca, Yasemin

doi:10.4274/jcrpe.galenos.2022.2021-10-4

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤ 18 Years Old.

Copy For Citation

Giles Senyurek Y., Iscan Y., Sormaz I. C., Poyrazoglu Ş., Tunca F.

Journal of clinical research in pediatric endocrinology, vol.14, pp.196-206, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 14
Publication Date: 2022
Doi Number: 10.4274/jcrpe.galenos.2022.2021-10-4
Journal Name: Journal of clinical research in pediatric endocrinology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
Page Numbers: pp.196-206
Keywords: BRAF(V600E) mutation, dynamic risk stratification, pediatric thyroid cancer, thyroid cancer, MANAGEMENT GUIDELINES, BRAF MUTATION, CHILDREN, RECURRENCE, ADOLESCENTS, CHILDHOOD, CARCINOMA, FEATURES, REMISSION, PROGNOSIS
Istanbul University Affiliated: Yes

Abstract

Objective: This study aimed to evaluate the role of risk stratification by the American Thyroid Association (ATA) pediatric thyroid cancer risk levels and BRAF(V600E) mutation to predict the response to treatment in papillary thyroid cancer (PTC) patients <= 18 years old.

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and <i>BRAF<sup>V600E</sup></i> Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤ 18 Years Old.

Abstract